Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2016/04/02
-
Journal
-
Indian UGC (journal)
-
Refrences75
-
Citations103
-
Joseph Ralph Kallini
-
Ahmed Gabr
-
Riad Salem
-
Robert J. Lewandowski
Cite
Kallini, Joseph Ralph, et al. “Transarterial Radioembolization With Yttrium-90 for the Treatment of Hepatocellular Carcinoma”. Advances in Therapy, vol. 33, no. 5, 2016, pp. 699-14, https://doi.org/10.1007/s12325-016-0324-7.
Kallini, J. R., Gabr, A., Salem, R., & Lewandowski, R. J. (2016). Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Advances in Therapy, 33(5), 699-714. https://doi.org/10.1007/s12325-016-0324-7
Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Advances in Therapy. 2016;33(5):699-714.
Journal Categories
Medicine
Medicine (General)
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
You May Also Like
- Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey
- Good and poor adherence: optimal cut-point for adherence measures using administrative claims data
- The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence oSf erectile dysfunction and related health concerns in the general population
- Screening Depressed Patients in Family Practice
- The Medical Risks of Obesity
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis | European Journal of Nuclear Medicine and Molecular Imaging |
| 68 | 2016 |
Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC | Liver International |
| 56 | 2015 |
Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma | Liver International |
| 104 | 2015 |
Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis | Liver International |
| 80 | 2015 |
In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Liver International |
| 72 | 2015 |
Refrences Analysis
The category
Medicine: Medicine (General) 40
is the most frequently represented among the references in this article. It primarily includes studies from Annals of Surgical Oncology The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT | Diagnostic and Interventional Imaging |
| 2024 | |
| Radiomics Features Extracted From Pre- and Postprocedural Imaging in Early Prediction of Treatment Response in Patients Undergoing Transarterial Radioembolization of Hepatic Lesions: A Systematic Review, Meta-Analysis, and Quality Appraisal Study | Journal of the American College of Radiology |
| 1 | 2024 |
| Immune Effects of Intra-Arterial Liver-Directed Therapies | Journal of Vascular and Interventional Radiology |
| 2024 | |
Energy window optimization in bremsstrahlung imaging after Yttrium-90 microsphere therapy | Biomedical Physics & Engineering Express |
| 2024 | |
| Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia | Journal of Hepatocellular Carcinoma |
| 2024 |
Citations Analysis
The category
Medicine: Medicine (General) 58
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Interventional Oncology in Hepatocellular Carcinoma and was published in 2016. The most recent citation comes from a 2024 study titled Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia. This article reached its peak citation in 2022, with 21 citations. It has been cited in 74 different journals, 24% of which are open access. Among related journals, the Cancers cited this research the most, with 7 citations. The chart below illustrates the annual citation trends for this article.